Absci to Participate in the 36th Annual Piper Sandler Healthcare Conference
ABSI 11.21.2024
About Gravity Analytica
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36thAnnual Piper Sandler Healthcare Conference in New York, NY.
Absci’s Founder & CEO Sean McClain is scheduled to participate in a panel discussion titled “The Promise of AI in Drug Development” on Thursday, December 5that 2:00 p.m. Eastern Time.
Interested parties may contact their Piper Sandler representative to request registration details for this live event.
About Absci
Absciis a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. OurIntegrated Drug CreationTM platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visitwww.absci.comand follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), andYouTube.
Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com
Media Contactpress@absci.com
